Q2 2025 · 13F-HR
Atlas Venture Life Science Advisors, LLCholdings as filed
Filed 2025-08-12 · accession 0001104659-25-076898
$662.4M
Reported value
11
Positions
2025-06-30
Period end
The Brief · Atlas Venture Life Science Advisors, LLC · Q2 2025
AI · grounded in 13F
Atlas Venture Life Science Advisors, LLC established a new position in Kymera Therapeutics, Inc. KYMR valued at $213.7M. The fund also initiated stakes in Disc Medicine, Inc. IRON for $126.3M and Dyne Therapeutics, Inc. DYN for $86.9M. Additional new positions include Sionna Therapeutics, Inc. SION, Third Harmonic Bio, Inc., and Vigil Neuroscience, Inc. VIGL.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $213.7M | 32.3% | 4,896,462 | Common | SOLE |
| 254604101 | IRON | Disc Medicine, Inc. | $126.3M | 19.1% | 2,384,456 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics, Inc. | $86.9M | 13.1% | 9,130,465 | Common | SOLE |
| 829401108 | SION | Sionna Therapeutics, Inc. | $64.1M | 9.68% | 3,694,020 | Common | SOLE |
| 88427A107 | — | Third Harmonic Bio, Inc. | $56.5M | 8.53% | 10,402,286 | Common | SOLE |
| 92673K108 | VIGL | Vigil Neuroscience, Inc. | $46.4M | 7.01% | 5,836,874 | Common | SOLE |
| 23954D109 | DAWNGBX | Day One Biopharmaceuticals, Inc. | $41.8M | 6.31% | 6,430,257 | Common | SOLE |
| 500946108 | KRRO | Korro Bio, Inc. | $14.2M | 2.14% | 1,137,149 | Common | SOLE |
| 45175G108 | — | Ikena Oncology, Inc. | $6.7M | 1.02% | 5,018,178 | Common | SOLE |
| 746964105 | QTTB | Q32 Bio, Inc. | $3.1M | 0.47% | 2,092,106 | Common | SOLE |
| 37148K100 | GBIOGBX | Generation Bio, Co. | $2.7M | 0.40% | 8,279,484 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.